Pfizer (PFE) CORRESP Correspondence with SEC

Pfizer Inc.

235 East 42nd Street

New York, N.Y. 10017-5755

June 15, 2011

VIA EDGAR

Securities and Exchange Commission

100 F. Street, N.E.

Washington, D.C.  20549

Attention: Jim B. Rosenberg

Re:	Pfizer Inc.
	Form 10-K for Fiscal Year Ended December 31, 2010
	Filed February 28, 2011
	Form 10-Q for the Quarterly Period Ended April 3, 2011
	Filed May 12, 2011
	File No. 001-03619

Dear Mr. Rosenberg:

This letter is to confirm the receipt of your letter dated June 8, 2011 regarding our April 27, 2011 response to your original comment letter dated April 13, 2011, regarding the filings referenced above. The Company believes that it will be able to provide you with a full response on or before July 7, 2011.

Please do not hesitate to contact me at 212-733-3222 with any questions or comments you may have.

Very truly yours,

/s/ Loretta V. Cangialosi

Loretta V. Cangialosi

Senior Vice President and Controller

cc:	Frank A. D’Amelio
	Executive Vice President, Business Operations and Chief Financial Officer
	Larry P. Bradley
	Partner - KPMG LLP